The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Enliven Therapeutics Inc shares valued at $134,957 were sold by Patel Anish on Sep 08 ’25. At $20.24 per share, Patel Anish sold 6,667 shares. The insider’s holdings dropped to 283,308 shares worth approximately $5.64 million following the completion of this transaction.
Also, Patel Anish purchased 20,001 shares, netting a total of over 403,020 in proceeds.
Before that, Hohl Benjamin had sold 3,250 shares from its account. In a trade valued at $67,039, the CHIEF FINANCIAL OFFICER traded Enliven Therapeutics Inc shares for $20.63 each. Upon closing the transaction, the insider’s holdings decreased to 3,250 shares, worth approximately $0.46 million.
As published in their initiating research note from Goldman on June 16, 2025, Enliven Therapeutics Inc [ELVN] has been a Buy and the price target has been revised to $37. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. As of September 09, 2024, H.C. Wainwright has initiated its “Buy” rating for ELVN. Earlier on June 11, 2024, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for ELVN stock.
Analyzing ELVN Stock Performance
On last trading session, Enliven Therapeutics Inc [NASDAQ: ELVN] rose 3.64% to $19.92. The stock’s lowest price that day was $18.8, but it reached a high of $19.97 in the same session. During the last five days, there has been a drop of approximately -0.45%. Over the course of the year, Enliven Therapeutics Inc shares have dropped approximately -13.39%. Shares of the company reached a 52-week high of $25.37 on 01/03/25 and a 52-week low of $13.30 on 04/10/25.
Support And Resistance Levels for Enliven Therapeutics Inc (ELVN)
According to the 24-hour chart, there is a support level at 19.16, which, if violated, would cause prices to drop to 18.39. In the upper region, resistance lies at 20.33. The next price resistance is at 20.73. RSI (Relative Strength Index) is 49.00 on the 14-day chart, showing neutral technical sentiment.
Is Enliven Therapeutics Inc subject to short interest?
Stocks of Enliven Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -0.18 million shares to 4.89 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 5.08 million shares. A decline of -3.78% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.82 of the overall float, the days-to-cover ratio (short ratio) decline to 11.82.
Which companies own the most shares of Enliven Therapeutics Inc (ELVN)?
In terms of Enliven Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 45.5 in the next 12 months, up nearly 136.73% from the previous closing price of $19.22. Analysts anticipate Enliven Therapeutics Inc stock to reach 52 by 2025, with the lowest price target being 39. In spite of this, 0 analysts ranked Enliven Therapeutics Inc stock as nan at the end of 2025. On April 09, 2024, Mizuho assigned a price target of “a Buy” to the stock and initiated coverage with a $34.
